This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Y-mAbs Therapeutics マネジメント
マネジメント 基準チェック /14
Y-mAbs Therapeuticsの CEO はMike Rossiで、 Nov2023年に任命され、 の在任期間は 1.83年です。 の年間総報酬は$ 4.56Mで、 15.5%給与と84.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.056%を直接所有しており、その価値は$ 216.74K 。経営陣と取締役会の平均在任期間はそれぞれ1.3年と7.8年です。
主要情報
Mike Rossi
最高経営責任者
US$4.6m
報酬総額
| CEO給与比率 | 15.48% |
| CEO在任期間 | 1.8yrs |
| CEOの所有権 | 0.06% |
| 経営陣の平均在職期間 | 1.3yrs |
| 取締役会の平均在任期間 | 7.8yrs |
経営陣の近況
Recent updates
Seeking Alpha • Aug 06
Y-mAbs Therapeutics: The Next Deal Showcases The Value And Challenges Of Biotech M&A
Summary Y-mAbs Therapeutics announced that it would be acquired at a >100% premium relative to recent trading. The deal showcases how little optimism there is in the biotech market at this time, even though recent investors are seeing substantial gains. This article lays out what SERB is going to get, and what I feel this transaction means for near-term biotech M&A. Read the full article on Seeking Alpha
ナラティブの更新 • Aug 06
Pipeline Developments And Radiopharmaceutical Advances Will Extend Global Reach
Despite improved profitability—with net profit margin rising to 12.26% and a lower future P/E of 47.56x—analysts have cut Y-mAbs Therapeutics’ consensus price target from $14.70 to $11.68, suggesting tempered growth expectations. What's in the News SERB S.A.S. agreed to acquire Y-mAbs Therapeutics for approximately $398.67 million ($8.6 per share); deal approved by Y-mAbs board and expected to close by December 31, 2025, subject to antitrust approval.分析記事 • May 16
Earnings Update: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
A week ago, Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) came out with a strong set of first-quarter numbers that could...分析記事 • Apr 29
Insufficient Growth At Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Hampers Share Price
Y-mAbs Therapeutics, Inc.'s ( NASDAQ:YMAB ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a strong...
新しいナラティブ • Mar 31
DANYELZA And Radiopharmaceuticals Realignment Will Energize Global Opportunities
Strategic realignment into DANYELZA and Radiopharmaceuticals could enhance revenue growth and operational efficiency through focused business units.分析記事 • Mar 07
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported And Analysts Have Been Cutting Their Estimates
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shareholders are probably feeling a little disappointed, since its shares...Seeking Alpha • Jan 24
Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials
Summary YMAB's naxitamab sales declined from Q3 2023 to Q3 2024, but the company has a strong cash runway, supporting operations until 2027. Upcoming data readouts for GD2-SADA in Q2 2025 are critical for assessing the viability of their radiotherapy platform, most notably concerns related to toxicity. Despite risks, YMAB's current market cap of $270 million may be a bargain if upcoming data provides a clear clinical direction. I reiterate a "Buy" sentiment, with reservations about naxitamab sales growth and the uncertain future of GD2-SADA. Read the full article on Seeking Alpha分析記事 • Jan 10
Benign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 26% Plummet
To the annoyance of some shareholders, Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares are down a considerable 26% in...分析記事 • Dec 10
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Nov 19
The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shareholders that were waiting for something to happen have been dealt a blow...Seeking Alpha • Oct 21
Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers
Summary Y-mAbs Therapeutics' naxitamab is approved for R/R High-Risk Neuroblastoma, with ongoing trials to expand its use, but the market size is limited. Financially, YMAB has a market cap of $644 million and a cash runway of 4-5 quarters, raising concerns about its ability to fund future R&D. The company is focusing on the SADA platform, but the lack of efficacy data makes it a speculative investment at this stage. Despite promising prospects, YMAB's low cash reserves and small market potential for naxitamab warrant a cautious investment approach. Read the full article on Seeking Alpha分析記事 • Sep 12
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares have had a really impressive month, gaining 33% after a shaky period...Seeking Alpha • Aug 12
Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)
Summary YMAB maintains a market valuation around $500 million, potential for substantial appreciation. Pipeline updates include expanding the naxitamab market and progressing SADA radioimmunotherapeutic. Financially, YMAB has $77.8 million in cash, growing product revenues, and a cash runway of 8-9 quarters. Read the full article on Seeking Alpha分析記事 • Jul 15
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...分析記事 • Jun 02
Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%
The Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • May 09
Y-mAbs: There's A Ceiling Here Somewhere
Summary Y-mAbs Therapeutics has experienced a significant recovery in value but lacks upcoming catalysts for near-term growth. Their approved therapy, naxitamab, has shown promising results in treating pediatric cancers. Y-mAbs' GD2-SADA pipeline project has potential but carries high risk, and the company's financials are stable for now. Read the full article on Seeking Alpha分析記事 • Mar 14
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Y-mAbs...分析記事 • Feb 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares have continued their recent momentum with a 66% gain in the last month...Seeking Alpha • Jan 14
Y-mAbs Therapeutics: A Monoclonal Antibody Play
Summary Y-mAbs Therapeutics' shares have rebounded massively since March 2023 due to the company's restructuring, extending its cash runway until 2027. The company's main commercial asset is Danyelza, a monoclonal antibody for the treatment of neuroblastoma, which has shown promising sales. Y-mAbs is also evaluating Danyelza for other indications and has a novel cancer treatment program called SADA, but these are still in early stages. Chase the rally or time to take some profits? A full investment analysis follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • Nov 13
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$22m |
| Mar 31 2025 | n/a | n/a | -US$28m |
| Dec 31 2024 | US$5m | US$706k | -US$30m |
| Sep 30 2024 | n/a | n/a | -US$24m |
| Jun 30 2024 | n/a | n/a | -US$25m |
| Mar 31 2024 | n/a | n/a | -US$22m |
| Dec 31 2023 | US$3m | US$110k | -US$21m |
報酬と市場: Mikeの 総報酬 ($USD 4.56M ) は、 US市場 ($USD 2.59M ) の同規模の企業の平均を上回っています。
報酬と収益: Mikeの報酬は増加しましたが、会社は利益を上げていません。
CEO
Mike Rossi (54 yo)
1.8yrs
在職期間
US$4,557,590
報酬
Mr. Michael Rossi, also known as Mike, serves as Chief Executive Officer, President & Director of Y-mAbs Therapeutics, Inc. since November 06, 2023. He has been Director at Nucleus RadioPharma, Inc. He had...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 1.8yrs | US$4.56m | 0.056% $ 216.7k | |
| Founder | 10.4yrs | US$2.08m | 0.82% $ 3.2m | |
| Executive VP | 1.3yrs | US$2.75m | 0.13% $ 496.8k | |
| Senior VP & COO | 7.8yrs | データなし | 0.028% $ 110.0k | |
| Senior VP & CTO | 9.7yrs | データなし | 0.11% $ 443.2k | |
| VP & Head of Investor Relations | no data | データなし | データなし | |
| Senior VP | less than a year | データなし | データなし | |
| Chief Development Officer & Chief Medical Officer | 1.3yrs | データなし | データなし | |
| Senior VP & Head of DANYELZA Business Unit | less than a year | データなし | データなし | |
| Senior VP & Radiopharmaceutical Business Unit Head | less than a year | データなし | データなし |
1.3yrs
平均在職期間
55.5yo
平均年齢
経験豊富な経営陣: YMABの経営陣は 経験豊富 とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 1.8yrs | US$4.56m | 0.056% $ 216.7k | |
| Founder | 10.4yrs | US$2.08m | 0.82% $ 3.2m | |
| Independent Chairman of the Board | 7.8yrs | US$262.79k | 0.070% $ 271.5k | |
| Independent Director | 7.8yrs | US$250.29k | 0.013% $ 50.0k | |
| Independent Director | 10yrs | US$227.79k | 0.013% $ 50.0k | |
| Independent Director | 7.8yrs | US$227.79k | 0.013% $ 50.0k | |
| Independent Director | 5.3yrs | US$237.79k | 0.013% $ 50.0k |
7.8yrs
平均在職期間
55yo
平均年齢
経験豊富なボード: YMABの 取締役会 は 経験豊富 であると考えられます ( 7.8年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2025/09/15 08:09 |
| 終値 | 2025/09/15 00:00 |
| 収益 | 2025/06/30 |
| 年間収益 | 2024/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Y-mAbs Therapeutics, Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| Peter Lawson | Barclays |
| Yun Zhong | Brean Capital Historical (Janney Montgomery) |
| Thomas Shrader | BTIG |